REFERENCES
1. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, et al. Updates in the management of brain metastases. Neuro Oncol 2016;18:1043-65.
3. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374:1344-55.
4. van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017;390:1645-53.
6. Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol 1993;111:773-5.
7. Lampert P, Tom M, Rider W. Disseminated demyelination of the brain following Co60 (gamma) radiation. Arch Pathol 1959;68:322-30.
8. Lampert PW, Davis RL. Delayed effects of radiation on the human central nervous system; Early and late delayed reactions. Neurology 1964:912-7.
9. Monro P, Mair W. Radiation effects on the human central nervous system 14 weeks after x-radiation. Acta Neuropathol 1968;11:267-74.
10. Milic M, Rees JH. Acute demyelination following radiotherapy for glioma: a cautionary tale. Pract Neurol 2017;17:35-8.
11. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-73.
12. Flowers A. Control of both oligodendroglioma and multiple sclerosis with chemotherapy with temozolomide: case report. Neurology 2013;80:105.
13. Miller RC, Lachance DH, Lucchinetti CF, Keegan BM, Gavrilova RH, et al. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2006;66:1178-86.
14. Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985;29:210-18.
15. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001;61:223-31.
16. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-7.
17. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, et al. CNS complications of radiotherapy and chemotherapy. Lancet 2009;374:1639-51.
18. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-95.
19. Thiessen B, DeAngelis LM. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 1998;55:705-10.
20. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-84.
21. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012;488:508-11.
